Hip implant registry reveals how long replacements last

NCT ID NCT02520544

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 472 adults aged 18-75 who received a specific type of hip replacement to see how long the implants lasted. Researchers used patient surveys and survival curves to measure device performance. The goal was to gather long-term data, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

472 people

The number who actually took part.

Start date

Jan 2012

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and non-pregnant female patients between 18-75 years of age. 2. Patients requiring uncemented primary Total Hip Arthroplasty (THA), suitable for the use of the Accolade stem and Trident/Tritanium cup. 3. Patients with a diagnosis of osteoarthritis (OA). 4. Patients who understand the conditions of the study and are willing and able to comply with the post-operative scheduled clinical and radiographic evaluations and the prescribed rehabilitation. 5. Patients who signed the Ethics Committee approved Informed Consent Form prior to surgery. Exclusion Criteria: 1. Patients who require revision of a previously implanted hip prosthesis. 2. Patients who had a THA on contralateral side within the last 6 months. 3. Patients who had a THA on contralateral side more than 6 months ago and the rehabilitation period outcome was considered unsatisfactory or not good (Harris Hip Score \< 85). 4. Patients who will need lower limb joint replacement for another joint within one year. 5. Patients requiring bilateral hip replacement. 6. Patients who have had a prior procedure of acetabular osteotomy. 7. Patients with acute femoral fractures 8. Obese patients where obesity is severe enough to affect subject's ability to perform activities of daily living (body mass index, kg/m2: BMI ≥ 35). 9. Patients with active or suspected infection. 10. Patients with malignancy - active malignancy. 11. Patients with severe osteoporosis, rheumatoid arthritis (RA), Paget's disease or renal osteodystrophy. 12. Patients immunologically suppressed, or receiving steroids in excess of physiologic dose requirements. 13. The patient has a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device or the patient has a neurological deficit which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period. 14. Female patients planning a pregnancy during the course of the study. 15. Patients with systemic or metabolic disorders leading to progressive bone deterioration. 16. Patients, who as judged by the surgeon, are mentally incompetent or are unlikely to be compliant with the prescribed post-operative routine and follow-up evaluation schedule. 17. Patients with other severe concurrent joint involvements, which can affect their outcome. 18. Patients with other concurrent illnesses, which are likely to affect their outcome such as sickle cell anaemia, systemic lupus erythematosus or renal disease requiring dialysis. 19. Patient with a known sensitivity to device materials. 20. Patients under the protection of law (e.g. guardianship).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthroplasty, replacement, hip are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amphia Ziekenhuis

    Breda, Netherlands

  • Harrogate and District NHS Foundation Trust

    Harrogate, United Kingdom

  • Maatschap Orthopaedie Ikazia

    Rotterdam, Netherlands

  • Orbis Medisch Concern

    Sittard, Netherlands

  • Rijnstate Arnhem

    Zevenaar, Netherlands

  • Skånevård Kryh Division Kirurgi och Ortopedkliniken Hässleholm

    Hässleholm, Sweden

  • St. Antonius Ziekenhuis

    Nieuwegein, Utrecht, Netherlands

  • Ziekenhuis Netwerk Antwerpen

    Antwerp, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.